Mölnlycke publishes 2020 Annual Report

April 7, 2021

The 2020 report shows the company achieved strong organic sales growth, partly through supplying personal protective equipment (PPE) during the COVID-19 pandemic.

The company also welcomed its new CEO Zlatko Rihter during the year and launched its innovative new negative pressure wound therapy (NPWT) solution Advance® Solo.

Performance highlights include:

· Organic sales growth of 18%

· Total net sales of 1,793 million EUR

· EBITDA of 536 million EUR

· 300 million extra items of PPE supplied

· Good progress towards sustainability targets

Download the 2020 Mölnlycke Annual report here.

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures.

Get to know us

About us
Products and solutions
Our knowledge
External links
Contact us

Get the details

Regulatory support
Products - Instructions for use
Media and press
Privacy Center
Terms of use
Cookie policy
Site map

Attention: The information provided in this site/page is intended solely for indicative purpose. While we have taken any precautions to ensure that the content of this site/page is both current and accurate, errors can occur. In all cases you should consult with the IFU accompanying the product before using the product.

The Mölnlycke, Alldress, Avance, BARRIER, Biogel, Biogel Eclipse, Biogel Orthropro, Biogel PI Pro-Fit, Biogel Sensor, Deep Defense, Easywarm, Elset, Epaderm, Exufiber, Granulox, Granudacyn, Hydrolock, EZ Derm, Hacdil-S, Hibi, Hibicet, Hibiclens, Hibidil, Hibiscrub, Indicator, Mefix, Melgisorb, Mextra, Mepiform, Mepilex, Mepiseal, Mepitac, Mepitel, Mepore, Mesalt, Mesoft, Mesorb, Mestopore, Neoderm, Normlgel, PI Indicator, PI UltraTouch, ProcedurePak, Reveal, Safetac, Setopress, Skinsense, Tubifast, Tubifast 2-way stretch and Tubigrip trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care group of companies.